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STAT3 activation in circulating myeloid-
derived cells contributes to retinal
microvascular dysfunction in diabetes
Mei Chen1* , Gideon Obasanmi1,2, David Armstrong1, Nuala-Jane Lavery1, Adrien Kissenpfennig1, Noemi Lois1 and
Heping Xu1
Abstract
Background: Leukostasis is a key patho-physiological event responsible for capillary occlusion in diabetic
retinopathy. Circulating monocytes are the main cell type entrapped in retinal vessels in diabetes. In this study, we
investigated the role of the signal transducer and activator of transcription 3 (STAT3) pathway in diabetes-induced
immune cell activation and its contribution to retinal microvascular degeneration.
Methods: Forty-one patients with type 1 diabetes (T1D) [mild non-proliferative diabetic retinopathy (mNPDR) (n = 13),
active proliferative DR (aPDR) (n = 14), inactive PDR (iPDR) (n = 14)] and 13 age- and gender-matched healthy controls
were recruited to the study. C57BL/6 J WT mice, SOCS3fl/fl and LysMCre/+SOCS3fl/fl mice were rendered diabetic by
Streptozotocin injection. The expression of the phosphorylated human and mouse STAT3 (pSTAT3), mouse LFA-1,
CD62L, CD11b and MHC-II in circulating immune cells was evaluated by flow cytometry. The expression of suppressor
of cytokine signalling 3 (SOCS3) was examined by real-time RT-PCR. Mouse plasma levels of cytokines were measured
by Cytometric Beads Array assay. Retinal leukostasis was examined following FITC-Concanavalin A perfusion and
acellular capillary was examined following Isolectin B4 and Collagen IV staining.
Results: Compared to healthy controls, the expression of pSTAT3 in circulating leukocytes was statistically significantly
higher in mNPDR but not aPDR and was negatively correlated with diabetes duration. The expression of pSTAT3 and
its inhibitor SOCS3 was also significantly increased in leukocytes from diabetic mice. Diabetic mice had higher plasma
levels of IL6 and CCL2 compared with control mice. LysMCre/+SOCS3fl/fl mice and SOCS3fl/fl mice developed comparative
levels of diabetes, but leukocyte activation, retinal leukostasis and number of acellular capillaries were statistically
significantly increased in LysMCre/+SOCS3fl/fl diabetic mice.
Conclusion: STAT3 activation in circulating immune cells appears to contribute to retinal microvascular degeneration and
may be involved in DR initiation in T1D.
Keywords: Diabetic retinopathy, SOCS3, Monocytes, Inflammation
Background
Diabetic microvascular damage affects the eye (retinop-
athy), kidney (nephropathy) and the nervous system
(neuropathy). Although hyperglycemia is the ultimate
cause of various diabetic complications, increasing
evidence suggests the involvement of inflammation in
the initiation and progression of microvascular
complications, including diabetic retinopathy (DR) [1, 2].
Inflammation is an adaptive response of the host to
endogenous and exogenous insults [3–5]. During dia-
betes, hyperglycaemia is a chronic insult to circulating
immune cells and vascular endothelial cells. Further-
more, various intermediate metabolic products such as
advanced glycation end-products (AGEs) and advanced
lipoxidation end-products (ALE) also constitute insults
to tissue cells [6–8]. Vascular endothelial damage is a
main pathology in DR and microaneurysms, a
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characteristic feature of DR, is believed to be the conse-
quence of endothelial and pericyte cell death [1].
Previous studies have shown that increased
leukocyte-endothelial interaction (leukostasis) is a
critical step in diabetes-induced retinal microvascular
degeneration [9–11]. Leukostasis is considered as a low-
grade intravascular inflammatory response [9] that occurs
from the early stages of diabetes, well before any detect-
able clinical manifestations have developed [9, 10].
Leukostasis may cause capillary closure, endothelial death
and, ultimately, breakdown of the blood-retina barrier
(BRB). Activation of both vascular endothelial cells and
circulating immune cells is essential for the increased leu-
kostasis in diabetes [11]. Early work in rodent models of
DR indicated that neutrophils and monocytes are key
immune cells involved in retinal leukostasis [11–13], and
adhesion molecules such as leukocyte function-associated
antigen-1 (LFA-1) and vascular cell adhesion molecule 1
(VCAM-1) play an important role in this process [14].
Serra et al. showed that CD11b+ bone marrow-derived
monocytes from diabetic mice expressed higher levels of
CCR5 [11], a chemokine receptor for which its polymor-
phisms have been associated with diabetes [15]. Clinical
studies in patients with type 1 diabetes (T1D) have sup-
ported this finding, in which monocytes from T1D pa-
tients are activated [16], express higher levels of adhesion
molecules such as integrins CD11a and CD11b [17, 18]
and have greater potency to bind to endothelial cells [18].
This study was undertaken to uncover the molecular
mechanism(s) underlying diabetes-induced leukocyte
activation. The results suggest that the expression of
phosphorylated signal transducer and activator of tran-
scription (pSTAT3) is increased in leukocytes from T1D
patients with early stages of DR and in the
Streptozotocin-induced rodent model of T1D. Deletion
of the negative regulator of STAT3, the suppressor of
cytokine signalling 3 (SOCS3) in myeloid cells, resulted
in increased pSTAT3 expression and uncontrolled
diabetes-induced leukocyte activation, increased leukos-
tasis and exaggerated retinal vascular degeneration.
Methods
Human participants
This study was approved by the Office for Research
Ethics Committees Northern Ireland (ORECNI, Ref 14/
NI/0084); all study procedures were performed in
accordance with the Declaration of Helsinki on research
involving human volunteers. Participants were recruited
from the eye clinics in the Belfast Health and Social Care
Trust, Northern Ireland, UK. Written informed consent
was obtained from all participants prior to the undertak-
ing of any study procedure.
The study was designed as a cross-sectional study of
T1D patients with DR. Participants were included in the
study if they were 18 years of age or older, had been di-
agnosed of having T1D and if they had either mild
NPDR or PDR (active or previously treated and inactive)
. Exclusion criteria included lack of DR; NPDR more
than mild or less than PDR; history of severe cardiac
diseases, malignancy within the past 5 years, infectious/
non-infectious inflammatory diseases within the previ-
ous 2 months; presence of active autoimmune disease;
history or concurrent use of immunosuppressive medi-
cations or steroids; pregnancy; kidney failure and/or
media opacities that would prevent adequate fundus
examination. All participants underwent a full ophthal-
mic examination, including detailed slit-lamp biomicro-
scopy and confirmation and grading of the presence of
mild NPDR or PDR. Twenty millilitre whole blood was
drawn into EDTA-treated blood collection tube for
evaluating STAT3 activation.
Experimental animal studies
Mice and induction of diabetes
C57BL/6 J WT mice, SOCS3fl/fl and LysMCre/+SOCS3fl/fl
mice (all in C57BL/6J background) were bred and main-
tained at the Biological Resource Unit of Queen’s Univer-
sity Belfast. All animals had free access to food and water
and were housed in a temperature- and light-controlled en-
vironment with 12 h light/dark cycle. All procedures were
approved by the Ethics Committee of Queen’s University
Belfast, and complied with the Home Office Animal (Scien-
tific Procedures) Act (UK) and the ARVO (Association for
Research in Vision and Ophthalmology) statement for the
use of animals in ophthalmic and vision research. Diabetes
was induced in 12-week male mice by administrating five
daily i.p. injections of Streptozotocin (STZ, Sigma-Aldrich,
Dorset UK) (50 mg/kg body weight) [19]. Non-fasting glu-
cose levels were tested 1 week after the animals were ren-
dered diabetic using glucometry (FreeStyle Lite, Abbott
laboratories, Dublin, Ireland); animals with glucose con-
centrations > 13 mmol/l were considered to have devel-
oped diabetes. Body weight and non-fasting glucose levels
were monitored biweekly. HbA1c levels were determined
using Glyco-Tek Affinity Column (Helena Biosciences
Europe, Gateshead, UK) when mice were sacrificed.
Whole blood RNA extraction and qPCR
Up to 50 μl of mouse whole blood was collected from
tail vein and added to RNAprotect blood tube (Qiagen,
Manchester, UK) immediately. RNA extraction from
whole blood was performed using RNeasy Protect
Animal blood kit (Qiagen) following the manufacturer’s
instruction. RNA quantity was measured using Nano-
Drop 1000 Spectrophotometer (Thermo Scientific,
Leicestershire, UK). The same amount of RNA from
each sample was reverse-transcribed to cDNA using
First Strand transcriptase (Invitrogen, Paisley, UK) with
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random primers following manufacturer’s instruction.
Real-time qPCR was performed using Roche SYBR Green
Master Mix (Roche, Basel, Switzerland) on Roche Light-
Cycler 480 (Roche). Primers to detect socs3 (forward:
cctttgacaagcggactctc, Reverse: gccagcataaaaacccttca) and
18S (aggggagagcgggtaagaga, reverse: ggacaggactaggcg-
gaaca) were designed using primer3 and synthesised by
Integrated DNA Technologies (Leuven, Belgium). Data
were analysed using delta delta Ct method after normal-
isation using housekeeping gene 18S.
Immunofluorescence staining
Whole mouse eyes were collected and fixed in 2% PFA/
PBS for 2 h before transferring to PBS and stored in
4 °C for further processing [20]. For retinal flatmount
staining, retinal tissues were permeabilised and blocked
in 1% BSA/PBS for 2 h and then incubated in primary
antibodies (Biotinylated Griffonia Simplicifolia Lectin I
Isolectin B4: 1:50, Vector laboratory, Peterborough, UK;
rabbit anti-mouse Collagen IV: 1:50, AbD Serotec®,
Kidlington, UK) overnight. After thorough washes,
samples were incubated with secondary antibodies
(Streptavidin FITC or goat anti-rabbit Alex Fluor 569, all
from Invitrogen, UK, 1:200) at room temperature for
2 h. Tissues were flatmounted on glass slides with
mounting medium and evaluated under confocal
microscope (EZ-C1 confocal system, Nikon UK Limited,
Surrey, UK).
Leukostasis assay
Leukostasis was evaluated using a protocol published
previously with slight modification [19]. Briefly, mice
were intravenously injected with 120 μl FITC labelled
Concanavalin A (Con A, Vector Lab, UK). After 20 min,
mice were deeply anaesthetised with pentobarbital and
perfused with PBS under controlled pressure. Eyes were
then collected and fixed in 2% PFA for 2 h. Retinas were
dissected and flatmounted for confocal microscopy.
Adherent Con A+ cells in retinal blood vessels were
counted manually.
Flow cytometric analysis in human and mice blood
samples
One hundred microliter of human whole blood and
50 μl of mouse blood incubated with/without 100 ng/ml
of IL-6 (20 min for human cells, 40 min for mouse cells)
were stained for pSTAT3 (Tyr705-FITC from BD biosci-
ences, oxford, UK for human; Tyr705-APC from
eBioscience for mouse) following the manufacturers’ in-
struction. Mouse IgG2a-FITC isotype control (BD Bio-
sciences) or mouse IgG2b Kappa Isotype control
(eBioscience) were used. Stained cells were examined by
FACS Canto II (BD Biosciences) and data were analysed
using the FlowJo software (Version 7, Tree Star, Inc.,
Ashland, OR, USA).
Thirty microliter of mouse blood were collected
through tail-vein prick to EDTA-treated tubes and incu-
bated with antibodies against leukocyte surface markers
including CD3, CD19, GR-1, CD11b, LFA-1 (1:100, BD
Biosciences), CD62L, (1:100, BioLegend, San Diego,
USA) and MHC II (1:100, eBioscience) for 30 min. Red
blood cells were then removed with lysis buffer (BD Bio-
sciences) and samples analysed by FACS Canto II (BD
Biosciences), and data were analysed using FlowJo
(Version 7, Tree Star).
Plasma were collected from control and diabetic mice
(with 3 months diabetes duration). Cytokines IL-6, IL-
10, TNFα, IFNγ, IL-1β and IL12/IL23p40 as well as
chemokine CCL2 were measured by Cytometric Bead
Array (CBA; flex set, BD Biosciences) following manu-
facturer’s instruction. Samples were analysed by FACS
Canto II (BD Biosciences) and data were processed by
using FCAP array software (BD Biosciences).
Data analysis
Data are expressed as means ± standard error of the
mean (SEM). Graphs and statistical analyses were per-
formed using GraphPad Prism 5 (Graphpad, San Diego,
CA, USA). Unpaired t test was used to compare two
groups; one-way ANOVA with Tukey’s post-hoc test was
used to compare three or more groups. Two-way
ANOVA was used to compare studies having four
groups (SOCS3fl/fl controls, SOCS3fl/fl diabetes, LysM-
Cre/+SOCS3fl/fl controls, LysMCre/+SOCS3fl/fl diabetes). A
p value of < 0.05 was considered statistically significant.
Statistical Package for the Social Sciences, Windows
version 24 (SPSS; SPSS Inc., Armonk, NY, USA) was
used to carry out linear regression and correlation of
duration of diabetes and pSTAT3 expression.
Results
Increased expression of pSTAT3 in circulating leukocytes
in mNPDR
Forty-one T1D patients were recruited into this
study with mild non-proliferative diabetic retinop-
athy (mNPDR) (n = 13), active, untreated PDR
(aPDR) (n = 14) and treated and inactive PDR (iPDR)
(n = 14). Age- and gender-matched healthy controls
(n = 13) were also recruited. Characteristics of T1D
patients and healthy volunteers are summarised in
Additional file 1: Table S1. No statistically significant
differences were found between healthy controls and
DR patients in demographic factors such as age and
gender distribution. There were also no statistically
significant differences regarding gender and age
between healthy controls and patients with mNPDR
or active or inactive PDRs. The expression of
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pSTAT3 in circulating leukocytes with or without IL6
stimulation was examined by flow cytometry (Fig. 1a). A
statistically significantly higher percentage of pSTAT3+
leukocytes was observed in T1D patients compared with
healthy controls (Fig. 1b). When DR patients were further
grouped into mNPDR and aPDR, a statistically significant
increased number of pSTAT3+ leukocytes was observed in
mNPDR, but not aPDR, compared to healthy controls
(Fig. 1c).
Diabetes duration is a risk factor for development and
progression of DR. A statistically significantly negative
correlation between durations of diabetes and pSTAT3
expression [baseline, unstimulated expression (Fig. 1d)
and IL-6 stimulation (Fig. 1e)] was found. These results
suggest that a higher level of pSTAT3 expression in
circulating leukocytes is related to early stages of DR
and may contribute to the development of DR.
Activation of the IL6-STAT3-SOCS3 pathway in circulating
leukocytes in diabetic mice
To elucidate the role of the STAT3 pathway in diabetes-
induced immune cell activation and its contribution to
the initiation of DR, the STZ-induced type 1 diabetic
mouse model was used in the rest of the studies.
CBA assay showed that IL-6 was detected in plasma in
seven out of 13 diabetic mice with 3-month diabetic
Fig. 1 pSTAT3 expression in circulating lekocytes from diabetes patients. a Representative image showing gating strategy (Alexa Fluor 488 vs SSC)
used to elucidate pSTAT3 expression on peripheral whole blood with/without IL-6 stimulation alongside either Alexa Fluor 488-conjugated Isotype
control or anti-STAT3 (pY705) staining. b The percentage of total pSTAT3+ circulating leukocytes in unstimulated whole blood of all T1D patients (n =
39) compared with healthy control (n = 13). c The percentage of total pSTAT3+ circulating leukocytes in unstimulated whole blood of health control
(n = 13), mNPDR (n = 13) and aPDR (n = 14). d, e Correlation of T1D duration against percentages of circulating pSTAT3+ leukocytes without IL-6
stimulation (d) and with 20 min IL-6 stimulation (e). The B values (regression coefficient) reported in d, e are changes in pSTAT3 expression associated
with a unit (1 year) increase in T1D duration. The R2 is the magnitude correlation coefficient between T1D duration and pSTAT3 expression. b, c Data
are presented as mean ± SEM. b independent sample T test. c One-way ANOVA with Tukey’s post-hoc test. *p < 0.05; **p < 0.01. d, e Linear regression,
line on each graph is regression line. n = 40
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duration, but none in the non-diabetic control mice (n = 7
mice) (Fig. 2a, p < 0.05, Mann-Whitney test, two tails). IL-
10 and other cytokines such as TNFα, IFNγ, IL-1β and IL-
12 were below detectable levels (< 12 pg/ml) in both con-
trol and diabetic mice. Chemokine CCL2 was not detected
in the plasma of healthy control mice, but it was detected
between 10~50 pg/ml (22.31 ± 5.18 pg/ml) in diabetic
mice (p < 0.05, Mann-Whitney test).
STAT3 is activated through phosphorylation of tyro-
sine 705 (pSTAT3) leading to intranuclear translocation
and upregulation of a variety of inflammation/angiogen-
esis-related genes. Flow cytometry analysis of whole
blood after the stimulation of IL-6 showed that the per-
centage of pSTAT3+ leukocytes (Fig. 2b, c) and the
geometric mean of fluorescence intensity of pSTAT3
(Fig. 2d) were significantly higher in diabetic mice com-
pared with control non-diabetic mice. SOCS3 is a nega-
tive regulator of pSTAT3. Real-time RT-PCR analysis
showed that the expression of SOCS3 was increased in
circulating leukocytes from diabetic mice compared with
non-diabetic controls (Fig. 2e, p < 0.05). Our results
suggest the activation of the IL6-STAT3-SOCS3 pathway
in circulating leukocytes in diabetic mice.
Activation of circulating immune cells in diabetic mice
Flow cytometry analysis showed that the percentage of
CD11b+ or Ly6G+ leukocytes of total white blood cells
was significantly increased in diabetic mice (Fig. 3a).
The percentage of CD3e T cells did not significantly
change. Furthermore, the mean fluorescence intensity
(MFI) of adhesion molecule LFA-1 was increased, and
the expression of L-selectin (CD62L) and MHC-II was
decreased, particularly in CD11b+ myeloid cells
(Fig. 3b). L-selectin is constitutively expressed by all
immune cells and the expression is downregulated
upon activation. The results suggest that hypergly-
caemia increases the population of myeloid-derived
cells, induces their activation and upregulates the
adhesion molecule expression.
Fig. 2 Activation of the IL-6-STAT3-SOCS3 pathway in circulating leukocytes. a Plasma cytokine IL-6 in non-diabetic (CON, n = 7) and STZ-induced
diabetic mice (DM, n = 13). b The gating strategy to identify pSTAT3+ leukocyte by flow cytometry. FSC and SSC were used to identify blood
leukocytes. pSTAT3+ leukocytes were then identified. c The percentage of pSTAT3+ leukocytes in non-diabetic (CON, n = 5) and diabetic mice (3-
month diabetes duration, n = 4) after IL-6 stimulation. d The mean fluorescent intensity (MFI) of pSTAT3 in circulating leukocytes from control
(n = 5) and diabetic mice (3-month diabetes duration, n = 4) after 40 min IL-6 stimulation. e mRNA level of SOCS3 in circulating leukocytes in
control (n = 4) and diabetic mice (n = 8). Data were presented as mean ± SEM. a Mann-Whitney test, c–e Student t test. *p < 0.05; **p < 0.01
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Diabetes-induced myeloid cell activation is heightened in
LysMCre/+SOCS3fl/fl mice
Diabetes-induced leukostasis is known to be caused pre-
dominately by myeloid cells, e.g. neutrophils and mono-
cytes [10, 11]. To further understand the role of pSTAT3
in diabetes-induced myeloid cell activation, we used
LysMCre/+SOCS3fl/fl mice, in which SOCS3 was deleted
in myeloid cells resulting in spontaneous STAT3 activa-
tion [21–23]. Under non-diabetic conditions, there was
no significant difference between SOCS3fl/fl and LysM-
Cre/+SOCS3fl/fl mice in the distribution of different sub-
sets of circulating leukocytes, including CD3+ T cells,
CD19+ B cells, GR-1+ neutrophils, CD11b+ myeloid cells
and CD56+ NK cells [23].
LysMCre/+SOCS3fl/fl mice and SOCS3fl/fl mice devel-
oped comparable levels of diabetes upon STZ injec-
tion as they had similar levels of blood glucose
(Additional file 1: Figure S1A) and HbA1c (Additional
file 1: Figure S1B). Three months after the onset of
diabetes, the expression of pSTAT3 was increased in
circulating leukocytes and the increment was signifi-
cantly higher in LysMCre/+SOCS3fl/fl mice compared
with SOCS3fl/fl mice (Fig. 4a). The population of
CD11b cells was increased at a similar level in
SOCS3fl/fl and LysMCre/+SOCS3fl/fl diabetic mice
(Fig. 4b). The expression level of CD62L was down-
regulated (Fig. 4c), whereas the expression level of
LFA-1 (Fig. 4d) was upregulated in both SOCS3fl/fl
and LysMCre/+SOCS3fl/fl diabetic mice, although the
population of CD62L+ and LFA-1+ cells remained un-
changed among all groups (Fig. 4e). The diabetes-
induced upregulation of LFA-1 levels was significantly
higher in LysMCre/+SOCS3fl/fl mice compared with
that in SOCS3fl/fl mice (Fig. 4d). Our results suggest
that CD11b+ myeloid cells in LysMCre/+SOCS3fl/fl
mice were more active than those in SOCS3fl/fl mice
under diabetic conditions.
Deletion of SOCS3 in myeloid cells worsens diabetic
retinal vasculopathy
To understand whether increased circulating myeloid
cell activation in LysMCre/+SOCS3fl/fl diabetic mice leads
to more severe diabetic retinal vasculopathy, DR-related
vascular changes were investigated in SOCS3fl/fl and
LysMCre/+SOCS3fl/fl diabetic mice. Leukostasis was
examined by using the Concanavalin A-FITC labelling
technique. In healthy mice, 3~ 5 cells/retina were de-
tected and there was no difference between the two
strains of mice (Fig. 5a–c). One month after diabetes
induction, significantly higher number of Con-A+ leuko-
cytes were detected in the retinal vasculature of diabetic
mice when compared to that in the non-diabetic coun-
terpart controls (Fig. 5a–c). Furthermore, the number of
cells detected in LysMCre/+SOCS3fl/fl diabetic mice
(Fig. 5b, c) was significantly higher than that in
SOCS3fl/fl diabetic mice (Fig. 5a, c).
The evaluation of acellular capillaries was undertaken
using dual staining of Isolectin B4 (for endothelial cells)
and collagen IV (for blood vessel basal membrane).
Acellular capillaries have basal membrane but no endo-
thelial cells, therefore, are collagen IV positive and
Isolectin B4 negative (Fig. 5d–f ). A significantly higher
number of acellular capillaries were detected in LysM-
Cre/+SOCS3fl/fl diabetic mice than that in the SOCS3fl/fl
counterparts (Fig. 5, p < 0.05).
Discussion
Capillary occlusion is an early event of DR and a hall-
mark of retinal ischemia in patients with diabetes [10].
Entrapment of leukocytes inside retinal blood vessels
(leukostasis) is considered as an important contributory
factor to vascular damage, at least in experimental models
of DR [24–26]. Myeloid-derived cells are the predominant
cells in the process of leukostasis [11]. Herein, we showed
that pSTAT3 expression in circulating immune cells,
Fig. 3 Activation of circulating leukocytes in diabetic mice. a FACS analysis shows that CD11b+ myeloid cells, Ly6G+ neutrophils and CD3+ T cells in
control (n = 4) and diabetic mice (with 3-month diabetes duration, n = 5). b The mean fluorescence intensity (MFI) of CD62L, LFA-1 and MHC II in
circulating CD11b+ myeloid cells from healthy control (n = 6) and diabetic mice (n = 13). Data were presented as mean ± SEM. Student t test, * < 0.05
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including myeloid cells, is upregulated in T1D patients
with mNPDR but not aPDR, suggesting that STAT3 acti-
vation occurs early in DR and may contribute to the de-
velopment of this complication. STZ-induced diabetic
mice is a model representing early stages of DR (e.g. mild
vascular degeneration, BRB leakage but no severe ische-
mia and angiogenesis). Using this model, we found that
the IL-6/STAT3/SOCS3 pathway is activated in circulating
immune cells. Furthermore, using the LysMCre/+SOCS3fl/fl
mice, where the myeloid cells constitutively express
pSTAT3 due to the deletion of its inhibitor SOCS3, we
showed that uncontrolled STAT3 activation in myeloid
cells leads to more severe diabetes-induced retinal
vascular changes. Our results suggest that STAT3-driven
immune cell activation plays an important role in early
diabetes-induced microvascular degeneration.
Signs of mNPDR include microaneurysms and small
haemorrhages or transient BRB leakage [27, 28], which
are all related to microvascular damage. Previous studies
have demonstrated that STAT3 activation in endothelial
cells contributes to the early vascular damage in DR
[29–31]. STAT3 may contribute to the early vascular
damage through activating genes related to inflammation
and angiogenesis such as VEGF and hypoxia-inducible
factor 1 [32, 33]. STAT3 activation is also known to
be involved in hyperglycaemia-induced endoplasmic
Fig. 4 Myeloid cell activation in LysMCre/+SOCS3fl/fl diabetic mice. a Fresh blood were collected from WT and LysMCre/+SOCS3fl/fl mice without or
with 3-month diabetes and treated with IL-6 for 40 min. pSTAT3 expression was the examined by flow cytometry. Data showing are mean
fluorescent intensity (MFI) of pSTAT3 in circulating leukocytes from WT and LysMCre/+SOCS3fl/fl mice with and without diabetes. Student t test,
*p < 0.05. b The percentage of CD11b+ cells in SOCS3fl/fl and LysMCre/+ SOCS3fl/fl mice with and without 3-month diabetes. c, d The mean
fluorescent intensity (MFI) of CD62L (c) and LFA (d) in circulating leukocytes in SOCS3fl/fl and LysMCre/+ SOCS3fl/fl mice with and without diabetes.
e Percentage of CD62L+ and LFA-1+ leukocytes in SOCS3fl/fl and LysMCre/+ SOCS3fl/fl mice with and without diabetes. n = 4~ 6 per group. Data
were presented as mean ± SEM. Two-way ANOVA followed by Bonferroni test. *p < 0.05; **p < 0.01
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reticulum stress in endothelial cells [30]; inhibiting
NOX4 can attenuate high-glucose induced reactive oxy-
gen species (ROS) generation and STAT3 activation [29].
Our study suggests that STAT3 activation in leukocytes
also contributes to diabetes-induced vascular damage.
How leukocytes are activated in diabetes is not fully
understood. Circulating leukocytes originate from bone
marrow (BM) haematopoietic stem cells. A previous
study has shown that diabetic microenvironment impairs
the colony-forming capability of the BM resulting in
increased Ly6Chi (pro-inflammatory) circulating mono-
cytes [34]. In this study, the percentage of CD11b+ or
Ly6G+ leukocytes was significantly increased, whereas
the percentage of CD3 T cells did not change in the
STZ-induced diabetic mice. Further studies will be
needed to understand how other leukocytes such as NK
cells and B cells are affected by hyperglycemia in this
STZ-model. Recently, we have shown that under high
glucose conditions, bone marrow-derived macrophages
presented a more pro-inflammatory status [35]. It is
possible that the high glucose may induce the pro-
inflammatory phenotype of macrophages through the
STAT3 pathway as STAT3 can be activated by both
growth factor receptor and non-receptor tyrosine
kinases pathway [36]. Apart from hyperglycaemia, the
phenotype and function of circulating cells may also be
affected by cytokines, chemokines and other growth
factors in the plasma in diabetes. Increased levels of IL-6
and CCL2 have been observed in the plasma [37] as well
as in ocular fluids [38, 39] of patients with DR. We have
detected increased levels of IL-6 and CCL2 in the
plasma from diabetic mice. Neutrophils and monocytes
from diabetic patients produced significantly greater
amounts of superoxide [16, 40], and are the main
sources of pro-inflammatory cytokines [41]. These cyto-
kines and superoxide may affect circulating immune
cells and induce pSTAT3 expression [36].
STAT3 is a critical transcription activator in physio-
logical and pathological angiogenesis [42]. Previously, we
have shown that STAT3 activation in circulating
Fig. 5 Increased leukostasis and avascular capillaries in LysMCre/+SOCS3fl/fl diabetic mice. a–c Retinal leukostasis was evaluated by Con-A perfusion
in SOCS3fl/fl and LysMCre/+SOCS3fl/fl mice with/without 2-months diabetes and examined by confocal microscopy. a, b Representative confocal
images of retinal flatmount showing entrapped leukocytes (arrows) in diabetic SOCS3fl/fl (a) and LysMCre/+ SOCS3fl/fl (b). c Bar figure showing the
number of entrapped leukocytes in SOCS3fl/fl and LysMCre/+SOCS3fl/fl mice. d–f Acellular capillary was examined by confocal microscopy of
collagen IV (red) and Isolectin B4 (green) stained retinal flatmounts from in SOCS3fl/fl and LysMCre/+SOCS3fl/fl mice with/without 6-month diabetes.
Representative confocal images of retina flatmount stained with collagen IV (Red) and Isolectin B4 (green) in diabetic SOCS3fl/fl (d) and
LysMCre/+SOCS3fl/fl (e) mice. Acellular capillaries are positive for collagen IV but negative for Isolectin B4 (numbered). f Bar figure showing the
quantification of acellular capillaries. Data were presented as mean ± SEM. N > 6 per group. Two-way ANOVA followed by Bonferroni test. CON:
non-diabetes, DM: diabetes. *p < 0.05; ***p < 0.001
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immune cells contributes to the pathogenesis of neovas-
cular age-related macular degeneration [22]. Interest-
ingly, the expression of pSTAT3 in circulating immune
cells was not affected in aPDR patients and more im-
portantly, the expression level was negatively correlated
with the duration of diabetes. Macrophages are believed
to play an important role in pathogenic blood vessels
growth in PDR [43]. Our result suggests that the angio-
genic effect of macrophage in PDR is not driven by
uncontrolled STAT3 activation in their precursors, i.e.
monocytes in circulation. Indeed, late-stage diabetes
patients often suffer from impaired wound-healing and
reduced angiogenesis. However, our result does not rule
out the role of STAT3 in PDR as STAT3 can be
activated locally in the ischemic retina. When macro-
phages or other immune cells migrate to the ischemic
retina, they may undergo phenotypic switch and express
pSTAT3. Cytokines IL-6, IL-17 and growth factor VEGF
and PDGF are potent activators of STAT3, and the vitre-
ous levels of these cytokines/growth factors were signifi-
cantly higher in PDR patients compared with those in
cataract patients [44–46]. The role of pSTAT3 in the
pathogenesis of PDR warrants further investigation.
Conclusions
This study uncovered the novel role of the IL-6/STAT3
pathway in diabetes-induced circulating immune cell acti-
vation, and the development of diabetic retinal vasculopa-
thy. Targeting the IL-6/STAT3 pathway in myeloid cells
may be a novel approach for the prevention or the treat-
ment of retinal capillary occlusion in DR patients.
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